We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Scientific (TMO) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Thermo Fisher Scientific (TMO - Free Report) closed at $507.73, marking a -1.51% move from the previous day. This change lagged the S&P 500's daily gain of 0.07%. At the same time, the Dow added 0.02%, and the tech-heavy Nasdaq gained 0.01%.
Heading into today, shares of the maker of scientific instrument and laboratory supplies had lost 3.17% over the past month, lagging the Medical sector's loss of 1.58% and the S&P 500's gain of 0.38% in that time.
Thermo Fisher Scientific will be looking to display strength as it nears its next earnings release. On that day, Thermo Fisher Scientific is projected to report earnings of $5.66 per share, which would represent year-over-year growth of 11.42%. Our most recent consensus estimate is calling for quarterly revenue of $10.65 billion, down 0.29% from the year-ago period.
TMO's full-year Zacks Consensus Estimates are calling for earnings of $22.37 per share and revenue of $43.54 billion. These results would represent year-over-year changes of -3.74% and -3.07%, respectively.
Investors should also note any recent changes to analyst estimates for Thermo Fisher Scientific. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Thermo Fisher Scientific is currently sporting a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Thermo Fisher Scientific has a Forward P/E ratio of 23.05 right now. This represents a discount compared to its industry's average Forward P/E of 27.29.
Also, we should mention that TMO has a PEG ratio of 2.43. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. TMO's industry had an average PEG ratio of 2.07 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 111, putting it in the top 45% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher Scientific (TMO) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Thermo Fisher Scientific (TMO - Free Report) closed at $507.73, marking a -1.51% move from the previous day. This change lagged the S&P 500's daily gain of 0.07%. At the same time, the Dow added 0.02%, and the tech-heavy Nasdaq gained 0.01%.
Heading into today, shares of the maker of scientific instrument and laboratory supplies had lost 3.17% over the past month, lagging the Medical sector's loss of 1.58% and the S&P 500's gain of 0.38% in that time.
Thermo Fisher Scientific will be looking to display strength as it nears its next earnings release. On that day, Thermo Fisher Scientific is projected to report earnings of $5.66 per share, which would represent year-over-year growth of 11.42%. Our most recent consensus estimate is calling for quarterly revenue of $10.65 billion, down 0.29% from the year-ago period.
TMO's full-year Zacks Consensus Estimates are calling for earnings of $22.37 per share and revenue of $43.54 billion. These results would represent year-over-year changes of -3.74% and -3.07%, respectively.
Investors should also note any recent changes to analyst estimates for Thermo Fisher Scientific. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Thermo Fisher Scientific is currently sporting a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Thermo Fisher Scientific has a Forward P/E ratio of 23.05 right now. This represents a discount compared to its industry's average Forward P/E of 27.29.
Also, we should mention that TMO has a PEG ratio of 2.43. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. TMO's industry had an average PEG ratio of 2.07 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 111, putting it in the top 45% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.